On Nov. 12, we listed Moderna as a “must own” vaccine stock, as it traded at $85.18.
Just days later, it’s up to $95.71 and exploding on news its vaccine is 94.5% effective against the coronavirus. Preliminary analysis of data from more than 30,000 volunteers showed the vaccine prevented nearly all symptomatic cases of COVID-19.
In addition, according to a recent press release:
“The primary endpoint of the Phase 3 COVE study is based on the analysis of COVID-19 cases confirmed and adjudicated starting two weeks following the second dose of vaccine. This first interim analysis was based on 95 cases, of which 90 cases of COVID-19 were observed in the placebo group versus 5 cases observed in the mRNA-1273 group, resulting in a point estimate of vaccine efficacy of 94.5% (p <0.0001).”
“A secondary endpoint analyzed severe cases of COVID-19 and included 11 severe cases (as defined in the study protocol) in this first interim analysis. All 11 cases occurred in the placebo group and none in the mRNA-1273 vaccinated group.”
Together with Pfizer and BioNTech’s vaccine, also shown to be more than 90% effective, the U.S. could have two vaccines for emergency use by December with as many as 60 million doses available by the end of the year, as noted by Reuters.
“These are obviously very exciting results,” said Dr. Anthony Fauci, as quoted by CNN. “It’s just as good as it gets — 94.5% is truly outstanding.”
The news couldn’t come at a better time with U.S. cases passing 11 million.
States have been reporting higher numbers. Deaths and hospitalizations have been rising. And cases in Europe have been soaring. Hopefully, these vaccines do the trick, and life can resume some sort of normalcy moving forward.